Shin Nippon Biomedical Laboratories, Ltd. Recorded A 6.7% Miss On Revenue: Analysts Are Revisiting Their Models

Investors in Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) had a good week, as its shares rose 2.9% to close at JP¥1,438 following the release of its first-quarter results. Results look mixed - while revenue fell marginally short of analyst estimates at JP¥6.5b, statutory earnings were in line with expectations, at JP¥118 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Taking into account the latest results, the consensus forecast from Shin Nippon Biomedical Laboratories' twin analysts is for revenues of JP¥34.6b in 2026. This reflects a credible 3.8% improvement in revenue compared to the last 12 months. Statutory earnings per share are expected to sink 11% to JP¥108 in the same period. In the lead-up to this report, the analysts had been modelling revenues of JP¥34.7b and earnings per share (EPS) of JP¥110 in 2026. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

View our latest analysis for Shin Nippon Biomedical Laboratories

The analysts reconfirmed their price target of JP¥2,740, showing that the business is executing well and in line with expectations.

Of course, another way to look at these forecasts is to place them into context against the industry itself. We would highlight that Shin Nippon Biomedical Laboratories' revenue growth is expected to slow, with the forecast 5.1% annualised growth rate until the end of 2026 being well below the historical 18% p.a. growth over the last five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 15% annually. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Shin Nippon Biomedical Laboratories.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Shin Nippon Biomedical Laboratories' revenue is expected to perform worse than the wider industry. The consensus price target held steady at JP¥2,740, with the latest estimates not enough to have an impact on their price targets.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have analyst estimates for Shin Nippon Biomedical Laboratories going out as far as 2028, and you can see them free on our platform here.

Plus, you should also learn about the 3 warning signs we've spotted with Shin Nippon Biomedical Laboratories (including 1 which can't be ignored) .

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.